CardieX (ASX:CDX) Debt-to-Equity : 388.50 (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is CardieX Debt-to-Equity?

CardieX's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$5.92 Mil. CardieX's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$2.63 Mil. CardieX's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$0.02 Mil. CardieX's debt to equity for the quarter that ended in Dec. 2023 was 388.50.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CardieX's Debt-to-Equity or its related term are showing as below:

ASX:CDX' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.73 Med: 0.24 Max: 388.5
Current: 388.5

During the past 13 years, the highest Debt-to-Equity Ratio of CardieX was 388.50. The lowest was -5.73. And the median was 0.24.

ASX:CDX's Debt-to-Equity is ranked worse than
99.86% of 705 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs ASX:CDX: 388.50

CardieX Debt-to-Equity Historical Data

The historical data trend for CardieX's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardieX Debt-to-Equity Chart

CardieX Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Equity

Get a 7-Day Free Trial

0.65

0.38

0.18

0.32

-5.73

CardieX Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.11	0.32	0.64	-5.73	388.50

Competitive Comparison of CardieX's Debt-to-Equity

For the Medical Devices subindustry, CardieX's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CardieX's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CardieX's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CardieX's Debt-to-Equity falls into.

CardieX Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CardieX's Debt to Equity Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.806	+	0.483)	/	-0.748
	=	-5.73

CardieX's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.92	+	2.627)	/	0.022
	=	388.50

CardieX (ASX:CDX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CardieX Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CardieX's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CardieX (ASX:CDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CardieX Ltd (ASX:CDX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

55 Lime Street, Suite 301, Level 3, Sydney, NSW, AUS, 2000

Website

https://www.cardiex.com

CardieX Ltd is a global health technology company, developing solutions for health disorders. The AtCor Medical division develops medical devices for measuring arterial stiffness and central blood pressure waveforms based on its patented SphygmoCor technology. It also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. It reports in a single segment being sales of cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company has three reportable segments by geographic area namely the Americas includes, global pharmaceutical trials business, Europe includes, the Middle East and Africa and the Asia Pacific includes, Asia and Australia/New Zealand.

CardieX (ASX:CDX) Headlines

No Headlines